Substituted pyridino arylpiperazines useful in the treatment of benign prostatic hyperplasia
US6218396A · kind A · utility
3Cited by
1References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 18, 1999 |
| Grant date | Apr 17, 2001 |
| Priority date | — |
| Expiry date | Feb 18, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates a to a series of heterocyclic substituted piperazines of Formula I ##STR1## methods of treatment, pharmaceutical compositions containing them, and intermediates used in their manufacture. The compounds of the invention selectively inhibit binding to the .alpha.-1.sub.a adrenergic receptor, a receptor which has been implicated in benign prostatic hyperplasia. As such the compounds are potentially useful in the treatment of this disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.